IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
about
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute LeukemiaDetection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.Different Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation Sequencing-Based Antibody Repertoire Analysis.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones.Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia.Molecular detection of minimal residual disease in multiple myeloma.Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms.Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid MalignanciesSimple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
P2860
Q26781328-2BCB8563-E4F6-440E-8883-CEF89EEC09DBQ33614375-9982187E-AB87-466B-92E1-8583C950406FQ33627948-8F07ADAB-F3BD-4B0C-9272-47F4C3BE536AQ38672646-3F916C37-69D9-49EE-80CA-C9559A47906BQ38815331-D4EC930A-A230-4502-9D5B-4FE4D0719BDBQ38937419-20DB968F-D136-4595-B68B-32D67A858D13Q39035188-37CFC873-7029-487B-9FA8-3A7EE7EE11EEQ39329093-25436CE2-8CB9-49F6-A6FB-6AAD4C6CFDD1Q39406673-FFF49D5F-960B-46C8-A4D2-22E9373B8284Q39420711-F5FD4F66-B456-42DE-8F49-1F60FF6D0F4DQ40373599-5A41B4A4-D04F-4F02-A1CE-11E1283C427DQ43279252-698D4AC4-D534-4CA5-A001-971A91820BF4Q45348850-5FDBFF3B-25C3-4A11-9746-156FA3816D42Q46103668-159C9A24-846E-4C17-8028-967C62D972E9Q48330707-10F3E6B9-4CC4-4B5A-92CE-206AA4F0F088Q48371783-6C0A0AAF-FBAB-45A5-8C62-632E1D92BE7BQ50223693-5F688B4B-F870-4775-A927-5C75CC5E86DFQ50660084-B3348A6D-FC54-4384-98A7-A69545760C2AQ51200437-A0624BA0-37C2-4CA6-874F-9B21B67D790BQ52661221-FB458BC8-B7F6-4D0D-978C-D18772937949Q52735368-51371AF3-19E7-4089-874C-8B04AEFDB578Q52777494-D724F5A1-AB55-41DB-B1C5-56E6F99602C4Q54109030-646A6896-4C4D-4FE6-A34F-E06BDA59F24EQ58723303-C8421A75-478A-48CF-ACAF-F5FB5502102CQ58724470-C1A4C91D-C01B-47EB-96D3-FEA59CB0F44F
P2860
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@ast
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@en
type
label
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@ast
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@en
prefLabel
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@ast
IgH-V(D)J NGS-MRD measurement ...... d very high-risk ALL patients.
@en
P2093
P2860
P1433
P1476
IgH-V(D)J NGS-MRD measurement ...... nd very high-risk ALL patients
@en
P2093
Bryan Langholz
Chris Carlson
Cindy Desmarais
David Williamson
Donna A Wall
Ilan Kirsch
Julie M Gastier-Foster
Michael A Pulsipher
Michael Borowitz
Michael Kalos
P2860
P304
P356
10.1182/BLOOD-2014-12-615757
P407
P577
2015-04-10T00:00:00Z